Penumbra
Open
$318.47
Prev. Close
$318.39
High
$318.48
Low
$318.38
Market Snapshot
$12.5B
73.1
0.36
$1.19B
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,700 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,700 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Recently from Cashu
Penumbra's THUNDERBOLT Technology Receives FDA Clearance for Acute Ischemic Stroke Management
Penumbra, Inc. has achieved a significant milestone with the clearance of its innovative THUNDERBOLT™ technology by the U.S. Food and Drug Administration (FDA). This advancement plays a critical role…
Penumbra Reports Strong Results for CAVT™ in Treating Pulmonary Embolism in Latest Trial
Penumbra, Inc. announces significant advancements in the treatment of pulmonary embolism (PE) following the 90-day results of its STORM-PE trial, which were recently presented at the Society of Interv…
Penumbra's STORM-PE Trial Shows Advances in Treating Acute Pulmonary Embolism
Penumbra, Inc. (NYSE: PEN) announces promising results from its STORM-PE clinical trial, which demonstrates significant advancements in the treatment of acute pulmonary embolism. This pivotal randomiz…
Investor Rights Firm Investigates Penumbra's Acquisition by Boston Scientific for Securities Violations
Investor Rights Law Firm Investigates Penumbra Amid Acquisition by Boston Scientific In recent developments, Halper Sadeh LLC, a New York-based law firm specializing in investor rights, initiates an i…